Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
biote Corp. stock logo
BTMD
biote
$3.64
+3.0%
$3.58
$3.04
$8.44
$200.79M1.17193,275 shs25,800 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$3.35
+4.9%
$2.88
$2.01
$5.64
$222.53M1.811.13 million shs439,927 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.05
-1.4%
$1.10
$0.51
$2.45
$47.52M0.83287,108 shs14,678 shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$2.38
+22.9%
$1.47
$1.03
$12.02
$258.41M1.021.24 million shs4.23 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
biote Corp. stock logo
BTMD
biote
-13.48%-8.79%+1.73%-17.33%-46.43%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+2.90%+10.00%+8.14%-21.43%-1.85%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
+3.92%+2.91%-6.44%-23.74%+26.19%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-5.37%+2.65%+30.20%-11.01%-71.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
biote Corp. stock logo
BTMD
biote
3.933 of 5 stars
3.55.00.00.03.33.31.3
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.7747 of 5 stars
3.50.00.00.04.30.00.6
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.8547 of 5 stars
3.65.00.00.04.11.71.3
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.1288 of 5 stars
3.51.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
biote Corp. stock logo
BTMD
biote
3.00
Buy$8.00120.08% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3.00
Buy$12.00258.74% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.29
Buy$8.00665.55% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3.00
Buy$12.20411.74% Upside

Current Analyst Ratings Breakdown

Latest QNCX, CRDF, BTMD, and TNGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
4/14/2025
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/25/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $4.00
3/24/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
3/13/2025
biote Corp. stock logo
BTMD
biote
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
2/28/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $17.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
biote Corp. stock logo
BTMD
biote
$199.38M1.00$0.38 per share9.60($0.58) per share-6.27
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$587K379.10N/AN/A$1.56 per share2.14
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A$1.98 per shareN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$40.99M6.30N/AN/A$2.48 per share0.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
biote Corp. stock logo
BTMD
biote
$3.32M$0.6114.126.73N/A5.20%-32.41%22.26%8/14/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%8/14/2025 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$31.39M-$1.39N/AN/AN/AN/A-53.27%-22.73%8/12/2025 (Estimated)
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.74M-$1.22N/AN/AN/A-284.42%-49.64%-32.00%8/6/2025 (Estimated)

Latest QNCX, CRDF, BTMD, and TNGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.24-$0.34-$0.10-$0.34N/AN/A
5/12/2025Q1 2025
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
5/7/2025Q1 2025
biote Corp. stock logo
BTMD
biote
$0.06$0.08+$0.02$0.37$47.25 million$48.99 million
3/24/2025Q4 2024
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.19-$0.28-$0.09-$0.28N/A$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
biote Corp. stock logo
BTMD
biote
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
biote Corp. stock logo
BTMD
biote
N/A
1.50
1.16
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.74
4.74
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.33
9.53
9.53
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
8.00
8.00

Institutional Ownership

CompanyInstitutional Ownership
biote Corp. stock logo
BTMD
biote
21.68%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
biote Corp. stock logo
BTMD
biote
24.00%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
20.30%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
biote Corp. stock logo
BTMD
biote
19454.71 million46.78 millionNot Optionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million47.15 millionOptionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6045.47 million36.61 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
90108.39 million100.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

biote stock logo

biote NASDAQ:BTMD

$3.64 +0.11 (+2.97%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$3.34 +0.16 (+4.86%)
As of 12:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.04 -0.02 (-1.42%)
As of 12:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$2.38 +0.44 (+22.89%)
As of 12:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.